Sustained Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa in Parkinson’s Disease: 96-week Primary Treatment Period Results from an Ongoing Open-label Extension Study (P11-5.006)
Evaluate the long-term safety, tolerability, and efficacy of foslevodopa/foscarbidopa (LDp/CDp) in people with advanced Parkinson’s disease (PD) treated through week 96 of an open-label extension study (OLES).
Authors
- Victor S.C. Fung (ORCID: https://orcid.org/0000-0003-3085-2282)
- Jason Aldred (ORCID: https://orcid.org/0000-0001-7441-0967)
- Amy Spiegel (ORCID: https://orcid.org/0000-0001-9179-7964)
- Filip Bergquist (ORCID: https://orcid.org/0000-0002-3437-0267)
- Camille Carroll (ORCID: https://orcid.org/0000-0001-7472-953X)
- Cheney Matthews
- Jia Jia (ORCID: https://orcid.org/0000-0001-6395-9487)
- Megha Shah
- Erik Hvid Danielsen
Institutions
- Aarhus University (DK)
- AbbVie (United States) (US)
- Selkirk College (CA)
- University of Gothenburg (SE)
- University of Plymouth (GB)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208722
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78